PRIMARY STUDY

Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders

Key Findings:  Neutral CB1R antagonists (such as AM4113), CB2R agonists (JWH133, Xie2-64), and nonselective phytocannabinoids (cannabidiol, β-caryophyllene, ∆9-tetrahydrocannabivarin) have shown great therapeutic potential for SUDs, as shown in experimental animals. Several cannabinoid-based medications (e.g., dronabinol, nabilone, PF-04457845) that entered clinical trials have shown promising results in reducing withdrawal symptoms in cannabis and opioid users

Type of Study:  Meta-analysis

Study Result:  Positive

Study Location(s):  United States

Year of Pub:  2019


Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC), AM-x Synthetic Cannabinoids, JWH-x Synthetic Cannabinoids, Pharma THC, Tetrahydrocannabivarin (THCV)

Terpenes Studied:  ß-Caryophyllene

Receptors Studied:  CB1, CB2